We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cutaneous Leishmaniasis Diagnosed by Press Imprint Smear

By LabMedica International staff writers
Posted on 28 Aug 2014
The diagnostic method of choice for cutaneous leishmaniasis historically has been microscopic demonstration of the parasite and isolation of the protozoa in culture and detection of parasite DNA by molecular diagnostic methods.

However most cases of cutaneous leishmaniasis occur in areas without good health infrastructure where diagnostic laboratory facilities are limited, therefore a rapid, sensitive, and inexpensive test for the diagnosis of the disease is needed for use in rural, resource-limited, endemic settings.

Scientists at the Federal University of Ceará (Fortaleza, Brazil) collected skin biopsy samples from 75 patients with a clinical diagnosis of cutaneous leishmaniasis, from September 2011 to August 2013. More...
Two biopsy samples were taken from the borders of ulcers (lesions) using a 3-mm disposable punch. One biopsy specimen was fixed in 10% formalin and processed for histopathology and the other specimen was used for a Press-Imprint-Smear.

For the imprint, the biopsy sample was put on a glass slide, and another glass slide was used to cover the tissue fragment sandwiched in between. On a firm surface, the tissue fragment between both glass slides was squeezed or squashed. Pressure on the middle of the slides was made, and therefore, the juice and tissue cells were spread on both slides surfaces that were in contact with the sample. Smears were air dried, fixed in methanol, stained with Giemsa, and examined microscopically using a 100 × oil immersion lens.

In 69 (92%) patients, the diagnosis of cutaneous leishmaniasis was confirmed by the identification of amastigotes by one or both methods. In 64 (85.3%) patients, amastigotes were detected by Press-Imprint-Smear. In 33 (44%) patients, amastigotes were detected by histopathology, and in 28 (37.3%) patients, amastigotes were detected by both methods. In 36 (48%) patients, parasites were seen only by Press-Imprint-Smear, and in five (6.7%) patients, parasites were seen only by histopathology. Leishmania (Viannia) braziliensis was the only species in this area.

The authors concluded that the Press-Imprint-Smear method was quicker that the histological method as it only took about an hour and had a much higher sensitivity of 85.3% compared with histology at 44%. Considering its sensitivity, low cost, and simplicity, Press-Imprint-Smear is a valuable tool for diagnosing cutaneous leishmaniasis and potentially, other infectious diseases at the point of care in rural or resource-limited endemic regions. The study was published on August 11, 2014, in the American Journal of Tropical Medicine and Hygiene.

Related Links:

Federal University of Ceará



Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
PlGF Test
Quidel Triage PlGF Test
New
Silver Member
Quality Control Material
Multichem ID-B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.